Skip to content

A 40% Response Rate Could Put Erasca’s Experimental Cancer Drug in the Spotlight

In Simple Terms

Erasca says its experimental drug may work better and be easier to tolerate than a rival treatment for pancreatic cancer. But the evidence available so far is limited, and important details have not been shared. New results could help clarify whether the drug is promising, but company values and investor excitement are not proof that it works.

A Race to Target RAS

Attention is turning to ERAS-0015, an experimental drug being developed by U.S. company Erasca. The company is trying to show that its cancer treatment candidate could outperform Rasonk, a drug developed by Revolution Medicines. That raises two distinct questions: Is there a treatment signal worth investigating, and do the companies’ market values reflect what is actually known about the drugs? So far, the available information provides no definitive answer to either question.

Erasca describes ERAS-0015 as a broad-spectrum RAS pathway inhibitor. The company says its research in China produced a compound that is more potent and better tolerated than Rasonk, based on the comparison it has made. But that remains a claim from the company, not conclusive evidence of an independently established advantage. According to the report, the information released so far comes from limited data in an early-stage study and has been shared through press releases.

Here, “broad-spectrum” means that the drug is intended to target a wide range of forms of the RAS pathway, rather than focusing on just one narrow target. Describing a drug as more potent or easier to tolerate, however, requires a clear comparison of patient outcomes and side effects under suitable testing conditions. Promotional language alone cannot tell us how large any difference is, whether it would show up in larger trials, or whether it would hold up under detailed scrutiny.

This distinction matters because developing a new drug involves a series of stages, each of which addresses a different question. Early results may point to possible activity, but they cannot, on their own, show that patients live longer, enjoy a better quality of life, or experience the same benefit across a broader group. Without details of the study, it is not possible to judge how robust the signal behind Erasca’s claim is, or whether the initial finding can be confirmed.

What to Look for in the New Data

Erasca was scheduled to present another set of ERAS-0015 data on Friday at the joint EORTC, NCI, and AACR “TRIPLE” meeting in Barcelona. The meeting is a venue for presenting cancer research and studies related to the development of new treatments. But a drug’s appearance on a conference program does not make its results conclusive. Their significance depends on the details, the patients included, and how the data were collected and analyzed.

Before the presentation, CEO Jonathan Lim said at investor conferences that the drug’s overall response rate among patients with pancreatic cancer receiving second-line treatment or later could approach 40 percent. He said the figure would start with a four—in other words, be around 40 percent—and that the result would be meaningfully different from Rasonk. That is a company executive’s indication of what the data might show, not a substitute for reviewing the presentation itself.

The overall response rate measures the proportion of patients whose tumors respond according to the criteria used in a study. But it does not, by itself, tell doctors or patients everything they need to know. The figure alone does not reveal how long responses lasted, how many participants were included in the calculation, or how researchers handled patients who did not complete follow-up. Nor does it show whether the response occurred in comparable groups of patients or whether the treatment was tested directly against another drug.

The reported figure will therefore be more useful when read in context: the size of the patient group, how participants were selected, the length of follow-up, the definition of response, and the safety results. The information available here gives none of those details. It does not state the sample size or provide complete figures that could be analyzed. A signal approaching 40 percent should not be turned into a final verdict that the drug is superior or that it delivers a confirmed benefit to everyone who receives it.

Why the Comparison with Rasonk Matters

Erasca is positioning its drug against Rasonk, developed by Revolution Medicines, and is betting that its forthcoming results will look different. But a meaningful comparison between two drugs depends on whether the data were gathered under similar conditions. If the patients’ characteristics, trial designs, or measurement methods differ, simply placing two response rates side by side may not show which treatment is better.

Even if one trial reports a higher response rate, it remains important to ask whether the difference is reliable. Did it result from the drug itself, from differences among the patients enrolled, from a small number of participants, or from the length of time outcomes were observed? The available information does not answer these questions. Erasca’s comparison should therefore be treated as a hypothesis awaiting a proper test, not as an established fact.

Caution is especially important because the discussion concerns patients receiving second-line treatment or later. That means the drug is being studied after an earlier treatment, or after more than one stage of treatment, depending on how treatment lines are defined. The published information does not describe the participants’ characteristics or the treatments they received before ERAS-0015. It is therefore impossible to conclude that all patients had comparable treatment histories. Details like these can change how any reported response rate should be interpreted.

Tolerability, another part of Erasca’s claim, also requires specific evidence. Saying that a drug is “better tolerated” does not tell us what kinds of side effects occurred, how often they happened, how severe they were, or how many patients had to stop treatment or change their dose. Without that information, it is impossible to know whether any difference matters to patients or how the two drugs actually compare. Claims about effectiveness and tolerability should not be blended into a single impression before enough detail is available to assess each one.

A Company’s Valuation Is Not a Clinical Result

The report puts Erasca’s market value at about $5 billion, compared with about $35 billion for Revolution Medicines. Erasca is therefore worth considerably less than its rival, a gap the report links to Revolution’s lead in the race. At the same time, the difference has fueled speculation that Erasca could become an attractive acquisition target.

But the valuation gap does not prove that Erasca is undervalued, just as it does not prove that Revolution has the clinically superior treatment. Market values reflect investor expectations as well as commercial and financial factors; a medical comparison requires detailed clinical results. Future expectations may help shape the price of a biotechnology company, but expectations are not the same as evidence showing how patients actually respond.

The gap between what is known and what is anticipated helps explain the interest in both Erasca’s stock and its drug. The company has a compelling story for investors: a new candidate, a public comparison with a larger rival, and a suggestion of a potential response rate near 40 percent in pancreatic cancer after prior treatment. But each part of that story needs to be kept in perspective. An investment narrative cannot replace an assessment of trial results, and speculation does not become proof simply because it sparks discussion about a possible acquisition.

If the upcoming data show encouraging treatment activity, that would be an important step, but not the end of the road. Further development would still need to establish the size and duration of the benefit, which patients are most likely to benefit, and how the benefits balance against side effects. If the details fail to support the impression created by the early signals, investors may reassess the opportunity. Either way, the value of the presentation lies in the information that can be examined—not in the expectations surrounding it.

What We Still Don’t Know

It is important to recognize the limits of the available information before reaching a conclusion. The published material does not say how large the early study was, how many patients received ERAS-0015, what doses were used, how long patients were followed, or how many responses went into the figure suggested indirectly. It is also unclear whether the new presentation will offer a direct comparison with Rasonk or present separate data alongside results reported previously.

The available information also lacks a detailed safety profile, a list of side effects, and results on survival or disease control. These are not minor omissions; they are essential to understanding whether the drug offers a practical benefit to patients. A response that lasts only a short time may mean something different from one that continues, and a drug that shrinks tumors in some patients may still raise challenges related to tolerability or how consistently patients benefit.

Calling a drug “more potent” does not, by itself, specify how much improvement to expect or whether the claim refers to an effect in a laboratory test or outcomes in patients. The available information provides neither a technical definition of the claim nor the data behind it. The most accurate description at this stage is that Erasca is proposing a possible advantage, while the complete data needed to judge that claim have not been presented in the material available.

That does not mean the anticipated results are without value. Their importance depends on how much detail they add. Readers need to know whether the figure near 40 percent came from a small or larger group, how response was defined, how long it was tracked, and what symptoms or side effects accompanied treatment. The clearer the information, the easier it will be to separate the scientific signal from the message aimed at investors—and to assess what the drug might mean for patients.

The Bottom Line

ERAS-0015 sits at the intersection of medical hopes and financial interest. Erasca says its candidate may be more potent and better tolerated than Rasonk, and has hinted at an overall response rate in the region of 40 percent among patients with pancreatic cancer receiving second-line treatment or later. But the evidence available so far is early and limited, while crucial details about the study’s size, safety results, response duration, and comparison methods are missing.

The market values—about $5 billion for Erasca and about $35 billion for Revolution Medicines—reflect the companies’ different positions and investor expectations, not a medical verdict on the quality of their treatments. The real question is what the data show when they can be examined, not what headlines or acquisition speculation might suggest. The new presentation could provide a signal worth following, but proving that one drug is better will require complete information, a fair comparison, and clinical evidence that goes beyond a first impression.